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Abstract
A library of 426 FDA-approved drugs was screened for in vitro activity against E. multilocularis metacestodes employing the
phosphoglucose isomerase (PGI) assay. Initial screening at 20 mM revealed that 7 drugs induced considerable metacestode
damage, and further dose-response studies revealed that bortezomib (BTZ), a proteasome inhibitor developed for the
chemotherapy of myeloma, displayed high anti-metacestodal activity with an EC50 of 0.6 mM. BTZ treatment of E.
multilocularis metacestodes led to an accumulation of ubiquinated proteins and unequivocally parasite death. In-gel
zymography assays using E. multilocularis extracts demonstrated BTZ-mediated inhibition of protease activity in a band of
approximately 23 kDa, the same size at which the proteasome subunit beta 5 of E. multilocularis could be detected by
Western blot. Balb/c mice experimentally infected with E. multilocularis metacestodes were used to assess BTZ treatment,
starting at 6 weeks post-infection by intraperitoneal injection of BTZ. This treatment led to reduced parasite weight, but to a
degree that was not statistically significant, and it induced adverse effects such as diarrhea and neurological symptoms. In
conclusion, the proteasome was identified as a drug target in E. multilocularis metacestodes that can be efficiently inhibited
by BTZ in vitro. However, translation of these findings into in vivo efficacy requires further adjustments of treatment
regimens using BTZ, or possibly other proteasome inhibitors.
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Introduction
Parasitic tapeworms (Cestoda) such as Taenia solium, Echino-
coccus granulosus and Echinococcus multilocularis are important
human pathogens causing neglected diseases. In total they are
estimated to account for 22–55 million disability-adjusted life years
(DALYs) and thereby are comparable to the leading parasitic
disease malaria (39 million DALYs) [1]. All three species grow as
adult tapeworms in the intestine of their final host, where eggs are
produced upon fertilization. After fecal shedding, the eggs
contaminate the environment, and oral uptake leads to infections
of intermediate hosts such as accidentally humans. Whereas adult
Echinococcus spp. do not affect their final host, Taenia spp.
infection in humans can lead to mild gastrointestinal symptoms
such as diarrhea and abdominal pain [2]. In their intermediate
host, tapeworms form the larval metacestode stage, which causes
severe diseases in humans such as neurocysticercosis (NC; caused
by T. solium), cystic echinococcosis (CE; caused by E. granulosus)
and alveolar echinococcosis (AE; caused by E. multilocularis).
Besides surgical removal of the parasites, which is not always
possible, other treatment options include drug-based therapy using
praziquantel and albendazole (ABZ) against NC, and ABZ and
mebendazole against AE and CE [2,3]. These drugs, however,
were not specifically developed for the treatment of cestode
infections, but rather represent general anthelminthics that are
currently also used against cestodes. While these compounds have
clearly improved the life expectancy and living conditions of
affected patients, novel therapeutic options are needed due to the
fact that there are cases where the drugs in use have proven
ineffective, toxicity has been reported, and/or resistance formation
has occurred [2,3].
For the identification of novel potential treatment options
against cestode infections, E. multilocularis represents the prime
model parasite. This is due to the fact that a metacestode culture
system allowing the long-term maintenance, proliferation and
differentiation of the larval stage has been developed, which
permits detailed studies of drug-mediated effects [4–6]. In
addition, comprehensive information on the E. multilocularis
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genome and transcriptome has been made publically available,
and advanced molecular biological techniques such as stem cell
cultivation and RNAi have been established [7,8].
AE, caused by E. multilocularis, represents the most deadly of
all helminth infections, with an estimated 18’235 new cases per
year, and the vast majority (over 90%) occurring in China [9].
European countries such as Switzerland, France and Germany are
regarded as hot-spots of endemicity, and within Europe an average
number of 168 new cases per year have been reported [9].
Although AE is rare, the severity of the disease results in an
estimated 600’000 DALYs, which renders the impact of AE
comparable to tropical diseases such as leprosy, dengue and
schistosomiasis [1]. Upon infection, metacestodes grow and
proliferate similar to a malignant tumor, mainly in the liver.
Metastases formation often occurs close by or at more distant parts
of the body. The continuous and infiltrative growth of metaces-
todes causes loss of function of affected organs. AE is fatal if not
treated appropriately. Currently applied chemotherapeutical
treatment options are not parasitocidal, but parasitostatic [3].
Thus, patients have to undergo chemotherapy for extended
periods of time, often lifelong, in order to avoid further growth and
spread of metacestode tissue.
A limited number of compounds were found to be active against
E. multilocularis metacestodes in vitro, including nitazoxanide and
derivatives [10,11], 2-methoxyestradiol [12], artesunate and semi-
synthetic derivatives [13], mefloquine and enantiomers [14,15],
dicationic compounds [15,16], imatinib [17], ruthenium(II)
phosphite complexes [18], and synthetic amino-ozonides [19].
For two compounds, the di-cationic diguanidino compound
DB1127 and mefloquine, profound anti-parasitic activities were
also detected in experimentally infected mice [14,16]. Unfortu-
nately, the lack of financial incentives and the technical difficulties
associated with working with Echinococcus parasites have ham-
pered efforts to develop more effective treatment against AE. We
therefore changed our focus towards drugs that are already
approved and marketed and that will easier find a way to
application. We have earlier developed a screening assay for the
identification of novel compounds that act against E. multi-
locularis metacestodes, which is based on the detection of
phosphoglucose isomerase (PGI) activity in medium supernatants
of in vitro-cultured metacestodes [10]. PGI is a prominent
component of metacestode vesicle fluid, which is released upon
damage by physical or chemical means. In this study we employed
the PGI assay to screen a library of 426 FDA-approved drugs for
in vitro effects on metacestodes. Our initial screen at 20 mM
yielded 7 compounds with negative impact on E. multilocularis
metacestode viability, many of which had well-defined mecha-
nisms of action, thus making them useful tools to study basic
biology in addition to being potential therapeutics. Of these
compounds, bortezomib (BTZ), a proteasome-inhibitor in use for
treatment of multiple myeloma [20] and mantle cell lymphoma
[21], was further characterized. We here demonstrate that the
proteasome represents a valid cestode drug target. Finally we also
assessed the applicability of BTZ in vivo by employing the mouse
model for secondary AE.
Materials and Methods
All chemicals were purchased from Sigma (St. Louis, MO), if
not stated otherwise. Cell culture reagents were from Gibco-BRL
(Zu¨rich, Switzerland), with the exception of Dulbecco’s modified
Eagle medium (DMEM) and fetal bovine serum (FBS) that were
ordered from Biochrom (Berlin, Germany). A commercially
available FDA-approved drug library containing 426 compounds
was purchased from Selleck Chemicals (Houston, TX), and
Bortezomib was obtained from Mobitec (Go¨ttingen, Germany).
In vitro culture and drug screening of E. multilocularis
metacestodes
E. multilocularis metacestode tissue material was retrieved from
euthanized BALB/c mice that had been intraperitoneally infected
with E. multilocularis metacestodes (isolate H95). Dissected
parasite material was prepared as described earlier [4]. In vitro-
cultured metacestode vesicles were used for experimental studies
after more than 6 weeks of in vitro cultivation when they were 2 to
4 mm in diameter [10].
FDA-library drugs were supplied as 10 mM stock solutions in
DMSO and were prediluted in medium 1:10 before use. Initial
screening on metacestodes was performed at 20 mM in singlets and
activity was defined as 50% or more of the internal control DB1127
at the same concentration. Morphological effects on vesicles were
also checked in parallel. Further assessments of compounds that
were active in the initial screen were done in triplicates at 20, 10, 5,
1 and 0.1 mM (and in addition 0.05 and 0.01 mM for EC50
calculation of BTZ) and averages as well as standard deviations
calculated in Microsoft Excel 2010. The protocol described by
Stadelmann et al was applied [10], which is based on the release of
PGI from metacestodes that are damaged during treatment.
Negative controls contained the corresponding amounts of DMSO.
As a positive control DB1127 (20 mM) [15,16] was applied. PGI
measurements were performed as described earlier [10], with the
difference that a 2300 EnSpire multilabel reader (Perkin-Elmer,
Turku, Finland) was used for measurement of increase in
absorbance at 340 nm. PGI activity was calculated in Microsoft
Office Excel 2010 from the linear regression of the enzyme reaction
over time and set into relation to the positive control DB1127. The
activity of the DMSO control was subtracted.
Author Summary
Tapeworms (cestodes) are a class of important human
pathogens, causing very severe diseases in man such as
alveolar echinococcosis (Echinococcus multilocularis), cystic
echinococcosis (E. granulosus) and neurocysticercosis
(Taenia solium). Current treatments are mainly based on
benzimidazoles that show some limited activity against
cestode larvae, but often do not kill them. These
compounds have to be taken for extended periods of
time, and can cause adverse side-effects. Cestode infec-
tions cause neglected diseases and the pharmaceutical
industry is generally not interested in investments for
developing novel bioactive compounds. In this study we
focus on a panel of FDA-approved drugs and assessed
them in E. multilocularis, which causes the most deadly of
all helminth infections. One compound, the anti-cancer
drug bortezomib, exhibits considerable in vitro activity
against E. multilocularis metacestodes, and we provide
evidence that it acts on the proteasome. In experimentally
infected mice bortezomib activity was lower than the
currently used albendazole and induced adverse effects.
Bortezomib is therefore not a useful drug for treatment of
Echinococcus larvae, but our results demonstrate that in
future studies the cestode proteasome should gain more
attention as a drug target.
Activity of Bortezomib against Echinococcus multilocularis
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Scanning (SEM) and transmission electron microscopy
(TEM)
In vitro-cultured E. multilocularis metacestodes were treated
with BTZ at concentrations of 0.01, 0.05, 0.1 and 0.5 mM for a
period of 5 days at 37uC, 5% CO2. They were washed once in
PBS and were fixed in 2.5% glutaraldehyde in 100 mM sodium
cacodylate buffer (pH 7.2) for 2 h, followed by post-fixation in 2%
OsO4 in 100 mM sodium cacodylate buffer for 2 h. Subsequently,
specimens were washed in distilled water, treated with 1% uranyl
acetate for 30 min, washed again in water, and dehydrated by
sequential incubations in ethanol (30–50–70–90–100%). For SEM
analysis, dehydrated specimens were finally immersed in hexam-
ethyl-disilazane and air dried under a fume hood. They were then
sputter-coated with gold and inspected on a JEOL 840 scanning
electron microscope operating at 25 kV. For TEM analysis, fixed
and dehydrated specimens were embedded in Epon 812 resin
(Fluka) and polymerisation was carried out at 65uC overnight.
Sections were cut on a Reichert–Jung ultramicrotome (Reichert–
Jung, Vienna, Austria), loaded onto 300-mesh copper grids (Plano
GmbH, Marburg, Germany), stained with uranyl acetate and lead
citrate, and were viewed on a Philips 400 transmission electron
microscope (Philips Electron Optics, Eindhoven, Holland) oper-
ating at 80 kV.
Sequence analyses
The E. multilocularis proteasome subunit beta 5 gene (psmb5) and
the proteasome subunit beta 1 gene (psmb1) were identified by BLAST
on the website www.genedb.org/Homepage/Emultilocularis. Amino
acid sequence analyses of PSMB5 of E. multilocularis (GeneDB
EmuJ_000590200_1, referred to as EmPSMB5), Homo sapiens
(UniProtKB/Swiss-Prot P28074) and Saccharomyces cerevisiae (Uni-
ProtKB/Swiss-Prot P30656) were performed by alignment in
ClustalW 2.1 and they were further analyzed based on the identified
binding sites and active residues of PSMB5 as described by Gille et al
and Groll et al [22,23].
Relative quantification of ubiquitinated proteins by
western blot
Ubiquitinated proteins in metacestodes were detected and
quantified by Western blot. In short, metacestode vesicles were
incubated in DMEM in the presence or absence of 10 mM BTZ
for 24 h at 37uC. Assays were carried out in triplicates. Vesicles
were washed in PBS, physically broken by pipetting, and vesicle
fluid was removed after centrifugation. After another wash in PBS,
metacestode tissue was taken up in RIPA (50 mM Tris-HCl
(pH 7.4), 1 mM EDTA, 150 mM NaCl, 0.1% SDS, 0.5% doc,
1% Tx-100) and incubated on ice for 40 min. Following
centrifugation for 30 min, at 4uC and 16’1006 g, the protein
concentration in the supernatant was determined by BCA protein
assay kit. 15 mg of each sample were separated by 12% SDS-
PAGE, blotted onto nitrocellulose, and Western blots were
incubated in Odyssey blocking solution (Licor Biosciences GmbH,
Bad Homburg, Germany) +0.1% Tween for 2 h. The primary
antibodies were applied overnight at 4uC in Odyssey blocking
solution (mouse anti-ubiquitin, 1:500, sc-8017 (Santa Cruz
Biotechnology, Heidelberg, Germany); rabbit anti-GAPDH,
1:1’000, ab36840 (Abcam, Cambridge, UK)). Secondary antibod-
ies were applied for 1 h at room temperature in Odyssey blocking
solution (anti-rabbit IR680RD 680, 1:10’000, Licor 926-68071;
anti-mouse IR800CW, 1:10’000, Licor 926-32210, Licor Biosci-
ences, Bad Homburg, Germany). After washing in PBS, proteins
were visualized in an Odyssey Scanner (Licor). Semiquantitative
analysis of signals was conducted in ImageJ Software 1.47 and
Microsoft Office Excel 2010.
Proteasome activity assay
Inhibitory effects of BTZ on the proteasome and chymotrypsin-
like proteases of E. multilocularis metacestode extracts were
assessed as described in Qiu et al [24]. In vitro-cultured
E. multilocularis metacestodes were washed in PBS and disrupted
with a 1 mL pipette. After further washing in PBS, vesicle tissue
was resuspended in proteasome buffer (1 M Tris-HCl pH 7.4,
1 mM EDTA, 2 mM ATP, 20% glycerol, 4 mM DTT) on ice and
sonicated at 4uC for 1 min in a Q700 Sonicator (Q Sonica,
Newtown, CT, USA) (Amplitude 20, alternating on/off cycles of
5 seconds). The cell extract was centrifuged at 16’1006 g for
10 min at 4uC and the protein content of the supernatant was
measured by Pierce BCA protein assay kit (Thermo Scientific,
Waltham, MA, USA). The proteasome activity assay was
performed in 96-well plates in triplicates, containing 150 mg of
cell extract each, and BTZ (solubilized in DMSO) was added (final
BTZ concentrations 100, 10, 1, 0.1, 0.01, 0.001 mM). DMSO was
added as a negative control, and incubations lasted for 1 h at
37uC. In some experiments, Halt protease inhibitor cocktail
(Thermo Scientific) was added prior to addition of the fluorogenic
substrate N-Succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcou-
marin (SLLVT-AMC, in 0.05 M Tris-HCl pH 8.0, 0.5 mM
EDTA) to a final concentration of 40 mM. Fluorescence (excitation
at 380 nm and emission at 440 nm) was measured over 120 min
in an EnSpire multilabel reader. Relative chymotrypsin-like
activity was calculated via the regression of product formation
over time and expressed as percentage of the DMSO control using
Microsoft Excel 2010.
Fluorescent zymography
Fluorescent zymography was performed basically as described
earlier [25]. Metacestode tissue extracts were suspended in non-
reducing sample buffer. Metacestode extracts (25 mg per lane) and
a positive control (bovine chymotrypsin, 5 ng per lane) were
separated by 12% SDS-PAGE (with only 0.075% SDS in the
stacking gel), after which the gel was washed two times for 30 min
in SDS-removal solution (2.5% Tx-100), followed by several wash
steps in water. Subsequently the gel was immersed in 0.05 M Tris-
HCl (pH 7.4), 10 mM CaCl2, 0.005% Tx-100, 200 mM SLLVT-
AMC, either in the presence of 20 mM BTZ or the corresponding
DMSO control. After incubation for 45 min at 37uC, the
fluorescent signal (365 nm) representing chymotrypsin activity
was detected on a transilluminator (Syngene, Cambridge, UK).
For the visualization of the marker, the gel was subsequently silver
stained and the markers transferred to the gel image in Adobe
Illustrator CS 11.0.
For detection of EmPSMB5 by Western blot, metacestode
extracts were prepared as described above and loaded on a 12%
SDS-PAGE at 100 mg per lane in non-reducing sample buffer.
Western blotting was basically performed as described above by
use of infrared-dyed conjugate antibodies and detection employing
the Odyssey scanner (1st antibody: anti-PSMB5, 1:1’000,
SAB2101895; 2nd antibody: goat anti-rabbit IR680RD 680,
1:10’000).
In vivo study on the efficacy of BTZ treatment in mice
experimentally infected with E. multilocularis
metacestodes
Experiments were performed according to Swiss Animal
protection law. 40 female BALB/c mice (source: Charles River,
Activity of Bortezomib against Echinococcus multilocularis
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Sulzfeld, Germany), 8 weeks of age with an average body weight of
20–25 g, were kept in a temperature-controlled 12/12 hours light
cycle room with food and water ad libitum. For infection, in vitro-
cultured metacestodes were broken with a 1 mL pipette tip,
centrifuged at 5006g for 5 min at room temperature, and the
resulting pellet was resuspended in an equal volume of PBS. All
mice were infected intraperitoneally (i.p.) with 200 uL of the
metacestode suspension. During the following 6 weeks, the mice
were adapted to honey feeding (Blu¨tenhonig M-Budget, Migros,
Switzerland diluted 1:1 in 1% carboxymethyl cellulose ( = honey/
CMC)) twice a week as described [26]. At 6 weeks post-infection,
mice were randomly distributed into 8 cages with 5 animals each.
Each treatment group consisted of 2 cages. Group 1: negative
control, received 100 mL honey/CMC suspension orally each day
and 100 mL of PBS/CMC with 2.8 mL DMSO injected i.p. once
per week. Group 2: albendazole control, received 200 mg/kg
albendazole (ABZ) in honey/CMC orally on a daily basis and
100 mL of PBS/CMC with 2.8 mL DMSO injected i.p. once per
week. Group 3: BTZ treatment, received 100 mL honey/CMC
suspension by daily oral application and 0.7 mg/kg BTZ in
100 mL PBS/CMC once per week. Group 4: combined ABZ and
BTZ treatment, received 200 mg/kg ABZ in honey/CMC orally
each day and 0.7 mg/kg BTZ in 100 mL PBS/CMC once per
week. The described treatment was pursued for the first 3 weeks.
After that, the treatment regime was adapted to a BTZ dosage of
0.5 mg/kg, but administered twice per week. This treatment was
performed for another 3 weeks. All other treatments remained the
same. After a total treatment duration of 6 weeks, mice were
euthanized by CO2. All parasite tissue was collected after necropsy
and the total parasite weight per mouse measured. To evaluate
data distribution, Shapiro-Wilk test was applied in the software R
version 3.0.1 (R core team, A Language and Environment for
Statistical Computing, R Foundation for Statistical Computing,
Vienna, 2013). Further, the data was analyzed by one-way
ANOVA and Bonferroni-adjusted P values calculated by Pairwise
T-Test in R. Data was visualized by boxplot in Microsoft Office
Excel 2010.
Ethics statement
The in vivo study was approved by the Animal Welfare
Committee of the Canton of Berne under the licence number BE
103/11. The study was performed in compliance with the Swiss
animal protection law (TschV, SR 455).
Results
In vitro screening of a FDA-approved drug library
identifies high activity of BTZ against E. multilocularis
metacestodes
A library of 426 FDA-approved drugs was screened employing
the metacestode based PGI assay, using an initial concentration of
20 mM and a treatment duration of 5 days. The complete results of
this screening are shown in Table S1. Seven of these drugs
exhibited more than 50% of the activity of DB1127, one of the
current lead compounds [15,16] and this was also confirmed by
macroscopical observations of the vesicles. The 7 active com-
pounds were further evaluated in a concentration series (20, 10, 5,
1, 0.1 mM) (Figure 1). Axitinib and amlodipine besylate turned out
to be wrong-positive hits in the initial screen and no longer showed
activity of more than 50% when tested at 20 mM in triplicates.
Five compounds (BTZ, sorafenib tosylate, crystal violet, cande-
sartan cilexetil and nitazoxanide) were shown to be still active at
20 mM, but for sorafenib tosylate and candesartan cilexetil the
activity was lost already at 10 mM. The other three compounds,
nitazoxanide, crystal violet and BTZ, retained their anti-parasitic
activity at lower concentrations (Figure 1). Crystal violet was not
further pursued, since it is a topical disinfectant that cannot be
used for internal drug application [27]. Nitazoxanide was also not
followed-up, as this compound had been already extensively
studied before and did not show beneficial effects in human
patients [11,28]. BTZ emerged as the most promising compound,
showing high anti-metacestode activity at concentrations below
1 mM, with a calculated EC50 of 0.6 mM.
Bortezomib treatment of E. multilocularis metacestodes
induces severe morphological and ultrastructural
changes
E. multilocularis metacestodes were subjected to 5 days BTZ
treatment at concentrations ranging between 0.01 and 0.5 mM,
and the effects were visualized by SEM (Figure 2). Metacestodes
are basically fluid-filled vesicles that are composed of an outer
acellular laminated layer that covers the entire surface of the
parasite, and an inner germinal layer that represents the living
parasite tissue. Treatment with 0.01 mM BTZ did not have a
dramatic effect on the morphology of the germinal layer
(Figure 2B). However, more pronounced morphological alter-
ations were observed after treatment with 0.05 mM BTZ and
higher (Figure 2C, D), which lead to partial separation of the
parasite tissue from the inner surface of the laminated layer. In
contrast, control incubations in the presence of the corresponding
amount of DMSO did not lead to any alterations and
metacestodes exhibited an intact germinal layer with normal
morphological features (Figure 2A).
Investigations using TEM confirmed these findings. Sections
through control metacestodes showed an intact germinal layer,
Figure 1. Activity of the most active drugs of the FDA library
against E. multilocularis metacestodes in vitro. The seven most
active drugs (more than 50% damage of the control DB1127 at 20 mM
after 5 days; BTZ, sorafenib tosylate, crystal violet, candesartan cilexetil,
nitazoxanide, amlodipine besylate and axitinib) of the FDA drug library
screen were further tested in triplicates by PGI assay at different
concentrations (20, 10, 5, 1, 0.1 mM) and for their anti-metacestode
activity in vitro. As a positive control, DB1127 was applied at 20 mM and
the different drug activities are expressed as percentage of the positive
control. DMSO served as a negative control at same dilutions as the
drugs and was subtracted from all values. Note the high activity of BTZ
down to the concentration of 0.1 mM.
doi:10.1371/journal.pntd.0003352.g001
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composed of numerous cell types that form the parasite tissue
(Figure 3A, B). The most distal part of the parasite tissue is
composed of the tegument, a syncytial layer that surrounds the
entire metacestode, with numerous microtriches protruding into
the laminated layer. The adjacent metacestode tissue is composed
of undifferentiated cells with a large nucleus and nucleolus (also
described as germinative or stem cells), and differentiated cell types
such as glycogen storage cells, muscle cells, nerve cells and
connective tissue (Figure 3A, B). Treatment with 0.01 mM BTZ
did not notably affect the ultrastructure of the germinal layer
(Figure 3C, D). However, treatment with 0.05 mM had a major
impact, with parasites exhibiting clear signs of apoptosis (Figure 4).
Overall, BTZ treatment was followed by a distinct degeneration of
the tegumental structure and in particular of the microtriches
(Figure 4A, C). In many parts, however, the cellular membranes
were still intact, and also in undifferentiated cells the nucleus
appeared to be seemingly unaffected, while the cytoplasm was
filled with distinct vacuoles containing membrane stacks and/or
electron-dense cytoplasmic inclusions, which were situated most
likely within the former mitochondria (Figure 4A, B and D). In
many instances, cells were harboring large cytoplasmic vacuoles
filled with membranous material that structurally resembled
autophagosomes (Figure 4B, E). Treatment with 0.5 mM BTZ
had an even more dramatic effect, and resulted in complete
destruction of the germinal layer within the 5 days of incubation
(Figure 4F).
Sequence analysis of EmPSMB5
In human patients, the anti-cancer drug BTZ inhibits the
proteolytic activity of the proteasome subunit beta 5 (PSMB5),
and, to a lesser extent, also the beta 1 subunit (PSMB1) [29]. In E.
multilocularis we identified proteins ortholog to PSMB5 and
PSMB1: EmuJ_000590200_1 (referred to as EmPSMB5) and
EmuJ_000252500_1 (referred to as EmPSMB1). For further
analysis we focused on the EmPSMB5 subunit since it is
predominantly inhibited by BTZ [29]. PSMB5 sequence align-
ments from E. multilocularis, H. sapiens and S. cerevisiae showed
that the E. multilocularis ortholog shares 61% identity with
H. sapiens and 52% identity with S. cerevisiae orthologs on the
amino acid level (Figure 5). The amino acids needed for
proteolytic function of this proteasome subunit are present in
EmPSMB5 (Figure 5). In addition, the amino acids involved in
binding of BTZ in human PSMB5 are also present in EmPSMB5
with one residue being changed (Serine 88 instead of Threonine,
see Figure 5). Thus the described molecular target of BTZ in
humans is also present in E. multilocularis.
BTZ is targeting the E. multilocularis proteasome
BTZ was developed as an anti-cancer drug that would target the
proteasome, and thus induces apoptosis of tumor cells [20]. While
TEM suggested that BTZ treatment of metacestodes resulted in
features resembling apoptotic cells, we investigated whether BTZ
also induced accumulation of ubiquitinated proteins, which
Figure 2. Scanning electron microscopical (SEM) assessment of BTZ-treated metacestodes. E. multilocularis metacestodes were treated
with the solvent DMSO (A), or with 0.01 mM (B), 0.05 mM (C) or 0.5 mM (D) BTZ for 5 days, and were processed for SEM. Note the distorted morphology
of the germinal layer (GL) in those specimens treated with 0.05 and 0.1 mM BTZ. Bars = 250 mM.
doi:10.1371/journal.pntd.0003352.g002
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Figure 3. Transmission electron microscopy (TEM) of untreated and BTZ-treated E. multilocularis metacestodes. Parasites were treated
with the solvent DMSO as a control (A, B) or with 0.01 mM (C, D) BTZ for 5 days, and were processed for TEM. (A, B) show metacestodes maintained in
the absence of BTZ at low (A) and higher (B) magnification. The most outer laminated layer (LL), the tegument (Te) and the inner germinal layer (GL)
Activity of Bortezomib against Echinococcus multilocularis
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are clearly discernible; mi =mitochondria. Black arrows point towards microtriches that originate at the tegument and protrude into the LL. In
parasites treated with 0.01 mM BTZ no alterations are evident (C, D). Undifferentiated cells and mitochondria exhibit a similar morphology as the
controls, microtriches (black arrows) are still intact. (C) shows a higher magnification view of microtriches. Bars in A= 4 mm; B= 1.6 mm; C= 0.5 mm;
D= 1.6 mm.
doi:10.1371/journal.pntd.0003352.g003
Figure 4. Transmission electron microscopical (TEM) assessment of BTZ-treated metacestodes. E. multilocularis metacestodes were
treated with 0.05 (A–E) or 0.5 mM (F) BTZ for 5 days, and were processed for TEM. (A) shows an overview of a section through the metacestode wall
after treatment with BTZ at 0.05 mM, (B–F) are higher magnification views of selected areas in (A). Profound changes occurred at the interface
between tegument (Te) and laminated layer (LL), with evident microtriches distortion (black arrows, A, C). The cytoplasm of germinal layer cells is
filled with electron dense deposits (marked by white arrow in (A) and designated as ed in (B) and (D)), and often vacuoles containing membrane
stacks (ms) resembling authophagosomes are visible (B, E and insert in E). Nuclei (nuc) appear still largely intact (A, B). Treatment with 0.5 mM BTZ
results in completely distorted GL and only residual LL (F). Bars in A= 2.1 mm; B= 0.5 mm; C=0.7 mm; D= 0.7 mm; E = 0.35 mm; F = 3 mm.
doi:10.1371/journal.pntd.0003352.g004
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represents another hallmark of proteasome inhibition. Ubiquitina-
tion levels in BTZ-treated and control metacestodes were followed
in relation to GAPDH as a reference protein by Western blot, and
treatment with 10 mM BTZ for 24 h led to a significant
accumulation of ubiquitinated proteins (Figure 6). To rule out
that this was due to an increased activity of ubiquitinating
enzymes, the proteolytic activity of the proteasome was assessed.
The fluorogenic molecule SLLVT-AMC was used as a substrate
for chymotrypsin-like proteases (such as PSMB5). Upon addition
of BTZ to E. multilocularis vesicle extract, a concentration-
dependent reduction in substrate cleavage was observed
(Figure 7A). In order to block other proteases that show
chymotrypsin-like activity, Halt protease-inhibitor cocktail, that
could also inhibit parts of the proteasome [30], was added. This
led to a more stable DMSO control and to complete absence of
substrate cleavage at BTZ concentrations of 1 mM and higher.
The IC50 of BTZ in E. multilocularis metacestode extracts without
Halt protease inhibitor was calculated to be 0.76 mM, and at 1 mM
BTZ reduced substrate cleavage by 38.460.9% as compared to
the DMSO control (Figure 7A). Inhibition of proteases by Halt
protease inhibitor led to a reduction of substrate cleavage by
3263.4%, and the combined BTZ and protease inhibitor
treatment completely abolished chymotrypsin-activity.
Inhibition of chymotryptic protease activity in vesicle extracts by
BTZ was further visualized after separation of the vesicle extract
by non-reducing SDS-PAGE and exposure of the gel to the same
substrate SLLVT-AMC. One clear chymotryptic active band was
visible at around 23 kDa (Figure 7B). Upon addition of 10 mM
BTZ this signal was strongly inhibited. Western blot analysis
revealed that EmPSMB5 had the same apparent molecular mass
as the chymotryptic active band from the parasite extract
(Figure 7C). In conclusion, BTZ has a strong impact on the
functionality of the proteasome of E. multilocularis.
Preliminary assessment of BTZ treatment in mice
secondarily infected with E. multilocularis metacestodes
reveals limited in vivo activity
The effects of BTZ treatment by i.p. injection were investigated
in secondarily infected Balb/c mice. Albendazole (in honey/
CMC) was applied p.o. as a positive control, and as a negative
control mice were treated with honey/CMC p.o. and PBS i.p. In
general, mild to heavy diarrhea was observed for all mice treated
i.p. with BTZ on the first and second day after injection. In
addition, BTZ-treated mice showed neurological symptoms such
as slight ataxia and reduced fur care eventually. One mouse of the
BTZ-treated group died during the course of the experiment. Due
to these adverse effects of BTZ, treatment was adjusted to a dosage
of 0.5 mg/kg instead of 0.7 mg/kg, which led to better health
status in long term, though diarrhea was still observed. After
another 3 weeks of treatment at lower BTZ concentrations, all
mice were euthanized, carefully examined and total parasite
weight determined. In the control group, proliferating metaces-
todes with many small vesicles and surrounding blood vessels were
found. In contrast, BTZ treatment led to whitish and unilocular
cysts, some of them being calcified (Figure 8A). ABZ and ABZ/
BTZ-treated mice also harbored similar whitish, unilocular cysts,
Figure 5. Amino acid sequence alignment of the proteasome subunit 5 beta of Saccharomyces cerevisiae, Homo sapiens and E.
multilocularis. The amino acids of the active core of PSMB5 are highlighted in light grey, amino acids involved in BTZ binding are highlighted in dark
grey (based on [22,23]). One amino acid is both part of the active core and involved in BTZ binding (T67 of E. multilocularis sequence). One amino acid
involved in BTZ binding shows a conservative replacement (TRS88). The E. multilocularis PSMB5 was 52% identical to S. cerevisiae PSMB5 and 61%
identical to the human ortholog. The alignment was performed in ClustalW2.1.
doi:10.1371/journal.pntd.0003352.g005
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some of them being as small as a 1–3 mm in diameter only.
Shapiro-Wilk test suggested that the measured cyst weights did not
follow a normal distribution (W = 0.7428, P = 6.76E-07), but
rather a log-normal distribution (W = 0.9685, P = 0.3366). One-
way ANOVA analysis of log-transformed values proved a
significant difference between the groups (p = 5.36E-07). Post-
Hoc analysis by Pairwise T-Test with Bonferroni-adjustment
showed that there was a highly significant reduction in the ABZ
and ABZ/BTZ-treated group as compared to the control
(p = 2.2e-05 and p = 1.3e-06, Figure 8B). BTZ treatment also led
to a reduction in parasite weight, albeit results were not significant
(p = 0.1224, Figure 8B). Thus, in vivo treatment with BTZ has a
clear effect on the morphological appearance of recovered E.
multilocularis tissue, but in terms of parasite weight no significant
reduction compared to untreated controls was observed.
Discussion
Chemotherapeutical treatment of AE relies on the application
of the two benzimidazoles ABZ and MBZ, which have been shown
to interact with beta-tubulin, and thus lead to distortion of
the cytoskeletal organization and associated functions within
E. multilocularis metacestodes. In this study, we characterized
the in vitro and in vivo activity of the proteasome inhibitor BTZ
and defined the proteasome as a drug target in this parasite. This
could have important implications also with regard to other
clinically relevant cestodes.
BTZ was identified through a metacestode in vitro screen of 426
FDA-approved drugs at an initial concentration of 20 mM. This is
the first time that such an extended screening with hundreds of
compounds against E. multilocularis has been performed. We
hereby employed an established assay, which demonstrates the
damaging impact of compounds by detection of PGI activity, an
enzyme that is abundant in the vesicle fluid and is released upon
distortion of the physical integrity of the parasite cyst. Further
concentration series of the most active drugs were performed and
showed that in particular 3 drugs were also very highly active at
lower concentrations: BTZ, nitazoxanide and crystal violet. The
current drug for treatment of AE, ABZ, was not identified as an
active compound within our screen of the FDA library. The issue
of false negative compounds staying undetected by employing the
PGI assay has arisen before [31]. A likely explanation for the
missing activity in vitro is that in vivo ABZ gets further
metabolized to its active derivatives albendazolsulfoxide and
albendazolsulfone. In addition, the impact of host immunity
cannot be simulated through in vitro testing.
The activity of BTZ (EC50 of 0.6 mM in the PGI assay) is much
higher compared to other drugs tested so far by the PGI assay (e.g.
mefloquine 32 mM, DB1127 6.1 mM, [14,16]). The pronounced
impact of BTZ on the structural integrity of the germinal layer of
E. multilocularis metacestodes was confirmed by electron micro-
scopical assessment. At a concentration of 0.05 mM the ultra-
structure of microtriches was severely affected and clear alterations
pointing towards cell death could be observed within the germinal
layer. Even though a minor morphological effect on stem cells was
observed by electron microscopy, BTZ is expected to be able to
efficiently inhibit the growth and survival of germinal layer cells as
they are actively metabolizing cells. This is crucial for a new
treatment option against AE, since stem cells are the central target
to prevent recurrence after drug treatment [32,33].
BTZ had been developed as a proteasome-inhibitor for the
treatment of multiple myeloma and mantle cell lymphoma
[20,21]. In protozoan parasites such as Plasmodium spp.
[34–40], Leishmania spp. [41–45], Toxoplasma gondii [46],
Figure 6. Accumulation of ubiquitinated proteins upon E.
multilocularis metacestode treatment with BTZ. E. multilocularis
metacestodes were treated in vitro with BTZ (10 mM) for 24 h in
triplicates and proteins extracted and visualized by Western blot (A, B).
Treatment with equal amounts of DMSO served as a negative control.
GAPDH was used as sample loading control (A), the anti-ubiquitin
antibody detected ubiquitinated proteins in each sample; M=Marker
(B). Semiquantitative analysis of ubiquitinated proteins was performed
in Image J and relative protein abundance shown in relation to the
untreated controls (C). This experiment was performed twice and lead
to similar results of 3.5 times accumulation of ubiquitinated proteins
upon BTZ treatment.
doi:10.1371/journal.pntd.0003352.g006
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Figure 7. Proteasome activity in E. multilocularis cell extracts can be inhibited by BTZ. Chymotrypsin-like activity of the E. multilocularis
proteasome was shown in cell extracts from in vitro-cultured metacestodes by applying the fluorogenic substrate SLLVT-AMC in solution (A) and in
gel (B). Addition of BTZ led to dose-dependent inhibition of this activity. A, in solution proteasome assay with and without Halt protease inhibitor (to
inhibit other proteases). As a control DMSO was added to same amounts as with the drug and the activity calculated as percentage from the DMSO
control. This experiment was performed in technical quadruplicates and was repeated three times, which led to similar results each time. B, in gel
assay to detect chymotrypsin-like activity in E. multilocularis cell extracts. Bovine chymotrypsin was used as positive control (C, 5 ng per lane), E.
multilocularis extract was loaded at 25 mg. On the left the gel was incubated with DMSO, on the right with BTZ at 10 mM. C, Western blot was
performed to detect the E. multilocularis proteasome subunit beta 5 (EmPSMB5). Note that this protein migrates at the same apparent molecular
mass as the active band in B that could be inhibited by BTZ. Experiments B and C were repeated both twice leading to the same results.
doi:10.1371/journal.pntd.0003352.g007
Figure 8. In vivo treatment of secondary E. multilocularis infected Balb/c mice with BTZ reduces parasite weight. Balb/c mice were i.p.
infected with in vitro-cultured E. multilocularis parasite material. After 6 weeks, treatment was performed for 6 weeks (5 days a week) with 265 mice
in each treatment group. Controls received honey/CMC p.o. and PBS i.p. ABZ received 200 mg/kg ABZ in honey/CMC and PBS i.p. BTZ received
honey/CMC p.o. and 0.7 mg/kg BTZ i.p. once a week for three weeks, then 0.5 mg/kg twice a week for another three weeks. ABZ/BTZ received ABZ
p.o. and BTZ i.p. as stated above. After euthanization parasite material was resected (A) and weighed (B). A, macroscopical assessment showed
proliferating metacestode masses with many big and small vesicles (see black arrows) in the control group. All treated groups showed less
metacestodes, especially less proliferating ones and more white and encapsulated, small cysts (see white arrows). B, parasite weight visualized by
boxplot. Statistical analysis of log-transformed data confirmed a highly significant parasite mass reduction with ABZ and ABZ/BTZ treatment.
doi:10.1371/journal.pntd.0003352.g008
Activity of Bortezomib against Echinococcus multilocularis
PLOS Neglected Tropical Diseases | www.plosntds.org 10 December 2014 | Volume 8 | Issue 12 | e3352
Trypanosoma cruzi [47,48] and T. brucei [49,50] the proteasome
has been long investigated as a potential drug target. In addition,
the anti-malarial activity of BTZ and one of its derivatives was
assessed earlier [51]. In helminths, however, the proteasome
largely received attention within the nematode species Caenor-
habditis elegans regarding developmental studies and in Schisto-
soma mansoni regarding studies on development and stress
response [52]. As a drug target BTZ has not been experimentally
addressed so far. However, it is worth mentioning that within the
framework of the recently completed Echinococcus and Taenia
genome sequencing project, the proteasome has been implicated
as a potential drug target [7].
The proteasome of eukaryotes is built of a core particle (20S)
and one or two regulatory particles (19S) that together form the
26S proteasome [53]. The 26S proteasome degrades proteins that
are conjugated to ubiquitin in an ATP-dependent manner. In
addition the 20S proteasome degrades unfolded, damaged,
mutated and short-lived proteins also in an ubiquitin- and ATP-
independent manner [54]. Thereby the proteasome takes over a
critical role in regulating cell survival and cell cycle control [55]. In
cancer cells, the inhibition of the proteasome leads to accumula-
tion of proteasome-regulated proteins such as cell cycle-regulatory
proteins, cyclin-dependent kinases, tumor suppressors and tran-
scription factors [55,56]. One of these is NFKB that is attributed a
crucial role in the activity of BTZ [55,56], but in cestodes the
NFKB pathway does not exist [7]. Upon treatment of cancer cells
with BTZ, reduced degradation of proteins of cell cycle control
leads to apoptosis [55,56]. Induction of apoptosis has been
previously postulated as a strategy to target cestode metacestodes
[7] and certain hallmarks of apoptosis have been observed in
protoscoleces of E. multilocularis [57,58]. Overall, inhibition of
the proteasome causes multiple effects, as this leads to functional
impairment of multiple proteasome-regulated proteins, especially
in actively dividing cells such as the E. multilocularis stem cells.
This makes the proteasome a very attractive drug target.
Therefore we further assessed the mode of action of BTZ in the
cestode E. multilocularis and the proteasome as a potential drug
target.
Exposure of in vitro-cultured E. multilocularis metacestode
vesicles to BTZ led to an accumulation of ubiquitinated proteins,
as expected for a drug that targets the proteasome. In yeast, BTZ
was described to inhibit the chymotryptic activity of the
proteasome by binding through its boronic acid residue to the
beta 5 subunit of the core particle, PSMB5 [23]. To a lesser extent
BTZ can bind also to the beta 1 subunit PSMB1, but this was not
further followed within this study [29]. To confirm that BTZ also
inhibited chymotrypsin-like activity of the E. multilocularis
proteasome, specific substrate cleavage was performed in solution,
and the calculated IC50 of BTZ was 0.76 mM, which largely
corresponds to the EC50 measured for metacestodes (0.6 mM), and
which is also in the range of the IC50ies of BTZ in cancer cells
(0.1 mM; [55]). Since BTZ inhibited the substrate cleavage activity
only to a certain degree, Halt protease inhibitor mix was added.
The effects of Halt protease inhibitor revealed that other, non-
BTZ sensitive proteases were cleaving the substrate in use. It can,
however, not be completely excluded that Halt also affects the
chymotrypsin-like activity of the proteasome, as it has been shown
by Yabe et al that one component (Aprotinin) has inhibiting
activity on all three active subunits of the proteasome [30].
Nevertheless, we included Halt protease inhibitor, because only by
this a stable DMSO control could be achieved. Thus, in-gel assays
were performed using the same substrate, which revealed that only
one band of chymotryptic activity was visible that could be
partially inhibited by BTZ.
Since BTZ inhibits the chymotryptic activity of the proteasome
[23], an ortholog to the beta 5 subunit was searched for in the
E. multilocularis genome data base, and one protein (EmPSMB5)
was identified. Sequence analysis showed that the amino acids that
are essential for proteolytic function [22] are conserved in
EmPSMB5 (Figure 4). It has to be highlighted that apart from
its main target PSMB5, BTZ can inhibit also other targets, such as
for example chymotrypsin (as shown in the control of Figure 7B),
cathepsins, chymase, and others, because BTZ is not a completely
specific inhibitor [59]. Western blot analysis of the chymotryptic
active band that could be inhibited by BTZ showed that
EmPSMB5 had the same apparent molecular mass. Taken
together, the proteasome of E. multilocularis represents a valuable
drug target for inhibitors that have little or no activity against the
proteasome of the host.
In an attempt to translate these in vitro findings into in vivo
efficacy, experimentally infected mice were treated with BTZ or a
combination of ABZ and BTZ, and the treatment effects were
compared to a standard ABZ treatment, or no treatment at all.
Morphological assessments showed that metacestodes from BTZ-
treated animals were encapsulated by connective tissue, which
limited proliferation. The degree of encapsulation was even more
pronounced in ABZ and ABZ/BTZ-treated mice. The reduction
in parasite weight, although evident in BTZ-treated mice
compared to the non-treated control, was not statistically
significant. In contrast the standard treatment with ABZ resulted
in a significant reduction of parasite weight compared to the
control. One of the reasons for the only moderate effectiveness of
BTZ against AE might be the model of secondary infection, which
results in parasite proliferation mainly in the abdomen. Upon i.v.
application of BTZ high drug levels could be detected in the liver,
but not in the abdomen [55] and BTZ was shown to be limitedly
active against solid tumors, as in contrast to hematologic tumors
[60]. Thus, in future in vivo studies in mice, primary (egg-)
infection should be performed that will result in parasite growth
mainly in the liver, and which would be more representative for
the natural situation and thus would reflect a more realistic
scenario.
The in vivo study confirmed previously described adverse effects
of BTZ in mice such as diarrhea, fatigue and neuropathy [61].
Although the initial treatment regime was based on previously
published studies [62–65], it had to be adjusted to a lower dosage
of BTZ than recommended due to the increased occurrence of
adverse side-effects that occurred upon prolonged duration of
treatment. However, it has also been shown that even though BTZ
induces neuropathy in 31–64% of the patients, there is full
neurological recovery in 86% of the cases, because BTZ binds
reversibly to the proteasome and after treatment all nucleated,
surviving cells can resynthesize new proteasomes [60]. For other
cytostatic drugs the recovery rate is usually lower (64–71%) [66].
In conclusion, we here demonstrate for the first time that a
proteasome inhibitor, BTZ, exhibits an excellent in vitro activity
against the cestode E. multilocularis. This study identifies the
proteasome as a highly interesting and valuable drug target in
cestodes. The divergence of the E. multilocularis proteasome from
the host cell proteasome implies that more selective inhibition of
the cestode proteasome should be feasible in future. The in vivo
activity of BTZ in the secondary mouse model for alveolar
echinococcosis did not provide satisfying results. Thus, further
adjustment of treatment regimens will be pursued. In parallel, new
generation proteasome inhibitors that exhibit better bioavailabil-
ity, higher selectivity and lower host toxicity [60] provide novel
starting points for the development of a treatment option for AE
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and other cestode infections that is based on inhibiting the
functional activity of the proteasome.
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